{
    "pmcid": "11477718",
    "qa_pairs": {
        "How do nanobodies differ from conventional antibodies in targeting viral proteins?": [
            "They can access epitopes that are less accessible to conventional antibodies.",
            "They are larger and more complex than conventional antibodies.",
            "They require a host cell to function effectively.",
            "They are derived from human immune cells."
        ],
        "What future research direction is suggested for improving ESM models?": [
            "Incorporating more diverse sequence data and improving modeling algorithms.",
            "Developing new types of nanobodies unrelated to SARS-CoV-2.",
            "Focusing exclusively on the structural analysis of viral genomes.",
            "Eliminating the need for experimental validation entirely."
        ],
        "What is a significant challenge mentioned in using ESM for nanobody design against SARS-CoV-2?": [
            "Accurately modeling dynamic interactions due to rapid mutation rates.",
            "Lack of sufficient computational power for large-scale simulations.",
            "Inability to synthesize nanobodies in laboratory settings.",
            "Difficulty in obtaining evolutionary data for SARS-CoV-2."
        ],
        "What is the primary role of Evolutionary Scale Modeling (ESM) in the design of SARS-CoV-2 nanobody binders?": [
            "Predicting protein structures and interactions using evolutionary information.",
            "Simulating the entire viral replication process.",
            "Designing vaccines by predicting immune responses.",
            "Mapping the complete genome of SARS-CoV-2."
        ],
        "What is the purpose of integrating experimental validation with ESM predictions in nanobody design?": [
            "To confirm the computational predictions by testing efficacy in laboratory settings.",
            "To replace computational predictions with experimental results.",
            "To eliminate the need for computational modeling.",
            "To solely focus on the synthesis of conventional antibodies."
        ]
    }
}